162 related articles for article (PubMed ID: 17804674)
21. mTOR inhibitors: do they help preserve renal function?
Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
[TBL] [Abstract][Full Text] [Related]
22. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis.
Kramer AB; Ricardo SD; Kelly DJ; Waanders F; van Goor H; Navis G
J Pathol; 2005 Dec; 207(4):483-92. PubMed ID: 16211543
[TBL] [Abstract][Full Text] [Related]
23. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin reduces proteinuria and renal damage in the rat remnant kidney model.
Esposito C; Villa L; Grosjean F; Mangione F; Esposito V; Castoldi F; Serpieri N; Arra M; Pertile E; Maggi N; Valentino R; Dal Canton A
Transplant Proc; 2009 May; 41(4):1370-1. PubMed ID: 19460562
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
Nakagawa S; Masuda S; Nishihara K; Inui K
Biochem Pharmacol; 2010 Jan; 79(1):67-76. PubMed ID: 19660439
[TBL] [Abstract][Full Text] [Related]
26. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
[TBL] [Abstract][Full Text] [Related]
29. Rapamycin attenuates the severity of murine adriamycin nephropathy.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Am J Nephrol; 2009; 29(4):342-52. PubMed ID: 18948688
[TBL] [Abstract][Full Text] [Related]
30. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
32. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
33. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
[TBL] [Abstract][Full Text] [Related]
34. Renoprotective effects of long-term oral nicotine in a rat model of spontaneous proteinuria.
Agarwal PK; van den Born J; van Goor H; Navis G; Gans RO; Bakker SJ
Am J Physiol Renal Physiol; 2012 Apr; 302(7):F895-904. PubMed ID: 22218593
[TBL] [Abstract][Full Text] [Related]
35. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
Cruzado JM
Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
[TBL] [Abstract][Full Text] [Related]
36. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
Zheng R; Wang L; Fan J; Zhou Q
Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
[TBL] [Abstract][Full Text] [Related]
38. The effects of rapamycin in the progression of renal fibrosis.
Damião MJ; Bertocchi AP; Monteiro RM; Gonçalves GM; Cenedeze MA; Feitoza CQ; Marques GD; Giannocco G; Mazzali M; Teixeira VP; Dos Reis MA; Pacheco-Silva A; Câmara NO
Transplant Proc; 2007 Mar; 39(2):457-9. PubMed ID: 17362758
[TBL] [Abstract][Full Text] [Related]
39. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
Huyghe E; Zairi A; Nohra J; Kamar N; Plante P; Rostaing L
Transpl Int; 2007 Apr; 20(4):305-11. PubMed ID: 17326771
[TBL] [Abstract][Full Text] [Related]
40. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
